FDA accepts Bayer finerenone filing: EUR 61 target for Bayer stock
Published on 10/23/2026 at 10:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSRegulatory progress and analyst view
- Bayer announced FDA acceptance of its finerenone application on October 8, 2026, with a 23 percent reduction in a key study risk.
- JPMorgan maintained its Overweight rating and EUR 61.00 target on October 1, 2026.
- Bayer stock trades at EUR 44.08 at 10:37 a.m. CEST at Lang & Schwarz on October 23, 2026, 0.29 percent below the Xetra close of October 22, 2026.
Bayer (ISIN DE000BAY0017) traded at EUR 44.08 at Lang & Schwarz on October 23, 2026, at 10:37 a.m. CEST, 0.29 percent below the Xetra close of October 22, 2026 at EUR 44.21. The latest company catalyst is the U.S. FDA's acceptance of Bayer's finerenone application, while JPMorgan retained a EUR 61.00 target on October 1, 2026.
Finerenone moves toward a new use
On October 8, 2026, Bayer said the FDA had accepted its supplemental application for finerenone in chronic kidney disease without diabetes. The company linked the filing to the Phase III FIND-CKD study, where finerenone reduced the risk of a key cardiovascular-kidney outcome by 23 percent versus placebo.
The filing is a regulatory step rather than an approval. FIND-CKD also showed a 0.7 ml/minute/1.73 m2 slower annual decline in estimated kidney function over 32 months, giving the pharmaceutical pipeline a measurable clinical basis.
What does the target imply?
According to finanzen.net on October 1, 2026, JPMorgan analyst Richard Vosser maintained an Overweight rating and a EUR 61.00 target. The same assessment warned that early third-quarter expectations could be too high because of timing effects in Crop Science.
That tension gives the upcoming results a clear test. Bayer reported first-half 2026 sales of EUR 24.30 billion, up 3.00 percent from the comparable period, while EBITDA before special items reached EUR 6.60 billion, up 7.00 percent, according to the Yahoo Finance earnings-call transcript. Investors will therefore compare the clinical progress with the operating evidence.
Three dates frame the story
On August 4, 2026, Bayer reported first-half sales of EUR 24.30 billion. On October 2, 2026, the company announced a USD 2.20 billion manufacturing investment in Ohio. On October 8, 2026, the finerenone filing reached the FDA acceptance stage with the 23 percent study outcome.
Results arrive on November 3
Bayer has scheduled its third-quarter 2026 results for November 3, 2026, at 7:30 a.m. CET, followed by the investor video call at 2:00 p.m. CET. Those dates will show whether the cautious agricultural expectations align with reported operating performance.
Stock holds near EUR 44
The Lang & Schwarz quote places Bayer stock at EUR 44.08 on October 23, 2026 at 10:37 a.m. CEST, 0.29 percent below the Xetra close of October 22, 2026 at EUR 44.21. The 52-week range is EUR 25.78 to EUR 53.92, and the market capitalization is EUR 43.3 billion as of October 23, 2026.
The further course of trading is shown by the continuously updated real-time quote of Bayer stock.
Bayer stock facts
- Company: Bayer Aktiengesellschaft
- ISIN: DE000BAY0017
- WKN: BAY001
- Ticker: BAYN
- Primary exchange: Xetra
- Price Lang & Schwarz (as of October 23, 2026, 10:37 a.m. CEST): EUR 44.08
- Change versus Xetra close: minus 0.29 percent
- Xetra close (October 22, 2026): EUR 44.21
- Market capitalization: EUR 43.3 billion (as of October 23, 2026)
- 52-week range: EUR 25.78-EUR 53.92 (as of October 23, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - General
- Index membership: DAX
- Next earnings date: November 3, 2026
Market context: Market report DAX.
